Biomedical subjects

V Jorgetti

Publications and source records attributed to V Jorgetti.

41 records · Page 3Linked to original sources

PubMedDate not supplied

[Mast cell hyperplasia in bone oxalosis].

BACKGROUND: To assess by means of histomorphometry the incidence of bone marrow mast cell hyperplasia in patients with chronic renal failure and oxalosis. MATERIAL AND METHODS: Eighteen individuals were assigned to three groups: 6 (4 males and 2 females, aged 26.31 +/- 2.5 yrs) had chronic renal failure (CRF) and oxalosis of bone; 6 (1 male and 5 females aged 22.1 +/- 3.56 yrs) had CRF and 6 normal (5 males and 1 female aged 23 +/- 2.78 yrs) individuals entered the control group. Quantitative histologic assessments were completed in undecalcified sections of plastic embedded iliac crest bone biopsies stained by the Toluidine Blue method for identification of mast cells. The number of mast cells (cell/mm2 tissue area, x +/- sd) was determined by a semiautomatic image-analyzing system. RESULTS: The number of mast cells was greater in patients with oxalosis of bone, 32.67 +/- 9.59, than in patients with CRF (20.84 +/- 5.04, p < 0.05) and than in the control group (3.26 +/- 1.03, p < 0.001). CONCLUSIONS: Oxalosis of bone is associated with substantial increases in the number of mast cells in the bone marrow. Such a change is not related to chronic renal failure per se and does not appear to represent a non-specific response to bone marrow fibrosis. Mast cell accumulation may contribute to the development of bone marrow fibrosis seen in this disorder.

Adult↗

PubMedDate not supplied

Methotrexate inhibition of bone mineral density increase in growing rabbits: prevention by folinic acid.

OBJECTIVE: Methotrexate (MTX) action on bone metabolism is as yet not completely understood. The results of clinical studies are controversial, since it is difficult to distinguish the side effects of MTX from those of the primary disease. This study assessed the effect of MTX, with and without folinic acid supplementation, on bone mineral density in growing normal rabbits. METHODS: Three groups of young NZW growing female rabbits were treated with: saline (n = 6) or MTX (0.25 mg/kg/week, n = 5) or MTX (same dose as above) plus folinic acid (0.25 mg/kg/week, n = 6) for a period of 3 months. The dose, duration and frequency of MTX administration were similar to the treatment of RA patients. The animals were submitted to dual-energy absorptiometry densitometry (HologicQDR 2000) before and after treatment; total body and L4-L5 BMD were evaluated. Histomorphometric analysis (L4 vertebrae) was also performed. RESULTS: Growing control rabbits showed increased total body BMD from a baseline of 0.180 +/- 0.006 to 0.198 +/- 0.007 gm/cm2 (mean +/- S.E.M, p < 0.006). In contrast, no increase in BMD (0.182 +/- 0.006 versus a baseline of 0.184 +/- 0.004, ns) was observed in the group treated with MTX, while the addition of folinic acid resulted in an increase in BMD values similar to controls, from a baseline of 0.181 +/- 0.004 to 0.198 +/- 0.003, p < 0.02), thus preventing adverse MTX bone effects. Average percent variations in BMD were +7.7%, -1% and +8.4% respectively. Spine (L4-L5) BMD showed analogous results, in line with the histomorphometric data. CONCLUSION: These results strongly support a deleterious action of MTX on bone metabolism, which is prevented by folinic acid supplementation. The potential clinical implications of our data are particularly significant for paediatric therapy.

Absorptiometry, Photon↗

PubMedDate not supplied

[Osteopetrosis: report of 2 cases and review of the literature].

Osteopetrosis is a rare inherited disease with incidence of 1:500.000 in north american population and characterized by increased skeletal density and fractures. Clinically three types can be distinguished: infantile malignant form, benign form of adult and intermediate type. We report two cases of intermediate form describing and commenting the clinical and radiological features.

Adult↗

PubMedDate not supplied

[Animal models of osteoporosis].

The authors review the literature regarding the animal models of osteoporosis in two main groups: The resorption-dominant models (oovariectomy, orchiectomy, limbs imobilization, calcium restriction and use of hormonies) and another group, the formation-deficit models (senil rats, SAM mouse, glucocorticoid administration or limbs imobilization.

Animals↗

PubMedDate not supplied

Histochemical staining of bone aluminum: comparison of aluminon and acid solochrome azurine and their correlation with bone aluminum content.

Aluminum (Al) may be a pathogenic factor in dialysis associated osteodistrophy. Aluminon and Acid Solochrome Azurine have been used for the detection of Al deposits in bone. We compared Aluminon and Acid Solochrome Azurine stains in normal (N) and uremic (U) rats. Both received intraperitoneal injections of aluminum chloride (AlCl3), until a cumulative dose of 5 mg/Al (NAL5; UAL5) or 30 mg/Al (NAL30; UAL30). The control groups received an equal volume of distilled water by means of intraperitoneal injections. Histomorphometric analysis showed that formation parameters (osteoid volume-OV/BV and osteoid surface-OS/BS), were significantly greater in the uremic groups than the control groups. In addition, the aluminum intoxication increased these values. When we compared the aluminum deposits in the undecalcified bone detected by both staining methods, we observed that Acid Solochrome Azurine was more sensitive than Aluminon in the normal renal function group and uremic treated with 5 mg of AlCl3. All our results were compared with atomic absorption spectrophotometry, showing that Al content presented a positive correlation with Aluminon stain in U and N rats, nevertheless it was not observed using Acid Solochrome Azurine stain. We conclude that histochemistry is important in diagnosing and monitoring aluminum bone disease.

Aluminum↗